Latest Daily News

More Stories
July 23, 2018

As mortality rates for breast cancer have improved in high-income countries over the last several decades, there is increasing focus on patient quality of life and avoiding long-term morbidities.

Read more

June 14, 2018

Inclusion of biologic factors in breast cancer staging in the American Joint Committee on Cancer (AJCC) eighth edition marks a significant change that highlights the importance of underlying tumor biology for staging.

Read more

June 5, 2018

Using adjuvant denosumab in an intense dosing schedule did not improve bone metastasis–free survival (BMFS) in patients with early-stage breast cancer who were receiving optimal locoregional and standard-of-care systemic adjuvant therapy, according to results from the D-CARE study.

Read more

June 5, 2018

A 6-month duration of adjuvant trastuzumab with chemotherapy was found to be noninferior to 12 months with chemotherapy, which is currently the standard of care, in Persephone, a phase III randomized clinical trial of women with HER2-positive early-stage breast cancer.

Read more

June 4, 2018

Endocrine therapy (ET) alone was noninferior to ET plus chemotherapy for women with estrogen receptor (ER)−positive, HER2-negative, axillary node−negative, early-stage breast cancer (BC) with a midrange score as measured by the Oncotype DX Breast Recurrence Score gene expression assay.

Read more

June 4, 2018

Adding the mutant-selective next-generation PI3K inhibitor taselisib to fulvestrant chemotherapy provides a small but statistically significant increase in investigator-assessed progression-free survival (INV-PFS).

Read more

June 4, 2018

Adjuvant denosumab improved disease-free survival (DFS) and is safe for postmenopausal women receiving an aromatase inhibitor (AI) for the treatment of nonmetastatic breast cancer, according to results from a large European study.

Read more

June 4, 2018

The Allen S. Lichter Visionary Leader Award was first presented in 2017 to honor those who have significantly changed the field of oncology or made outstanding contributions to further the mission of ASCO, CancerLinQ LLC, or Conquer Cancer through leadership and inspiration.

Read more

June 4, 2018

Endocrine therapy (ET) alone was noninferior to ET plus chemotherapy for women with estrogen receptor (ER)−positive, HER2-negative, axillary node−negative, early-stage breast cancer (BC) with a midrange score as measured by the Oncotype DX Breast Recurrence Score gene expression assay.

Read more

June 4, 2018

The combination of capivasertib plus paclitaxel resulted in a significantly prolonged progression-free survival (PFS) compared with paclitaxel alone among women with metastatic, triple-negative breast cancer (TNBC) with alterations in PI3K/AKT/PTEN.

Read more

June 3, 2018

Can some patients with cancer benefit from more aggressive treatment than standard regimens?

Read more

June 2, 2018

Therapies that target the protein HER2 have changed the landscape of cancer treatment, improving survival in advanced HER2-positive breast and gastric cancers.

Read more

June 2, 2018

The use of adjuvant chemotherapy to reduce the recurrence of breast cancer has been linked to significant improvements in mortality and morbidity, including disease-free survival (DFS) and overall survival (OS), in women with early-stage disease.

Read more
June 1, 2018

Saturday InBriefs: Scientific Highlights from ASCO18.

Read more

June 1, 2018

The Allen S. Lichter Visionary Leader Award recognizes ASCO members who have transformed the oncology field or significantly advanced the mission of ASCO, ASCO’s Conquer Cancer Foundation, or CancerLinQ LLC through leadership, vision, and inspiration.

Read more

May 17, 2018

Pilot Study of an Internet-based Self-Management Program for Symptom Control in Patients With Early Stage Breast Cancer.

Read more

May 15, 2018

Gabriel N. Hortobagyi, MD, FACP, FASCO, is the recipient of the 2018 Gianni Bonadonna Breast Cancer Award for his leadership and contribution in the field of translational medicine in breast cancer, with an exceptional record of mentorship.

Read more

May 14, 2018

During the 2012 ASCO Annual Meeting Plenary Session, Kimberly L. Blackwell, MD, of Duke University Medical Center, presented the primary results of the EMILIA trial.

Read more

May 13, 2018

The treatment paradigm of breast cancer has celebrated the successes of targeted therapy for decades. Currently, the hormone receptor and HER2 statuses of a breast tumor continue to drive the selection of therapy for patients with early-stage breast cancer and metastatic breast cancer (mBC).

Read more

May 11, 2018

Megan Kruse, MD, and Jame Abraham, MD, FACP, answer a question posed by an attendee during a Best of ASCO® Meeting.

Read more